These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Author: Vavra N, Salzer H, Sevelda P, Breitenecker G, Czerwenka K, Kucera H.
    Journal: Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161.
    Abstract:
    A prospective randomized study of 195 patients with endometrial cancer, who were treated by adjuvant hormone therapy, is reported. 100 patients received 100 mg medroxyprogesterone acetate alone, 95 a combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg). Our data show no statistical difference between the two groups.
    [Abstract] [Full Text] [Related] [New Search]